Therapy Detail

Therapy Name INCB040093 + Itacitinib
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
INCB040093 PIK3CD inhibitor 24 INCB040093 is a specific inhibitor of PIK3CD, which blocks PI3K/AKT signaling to prevent cell proliferation (NCI Drug Dictionary).
Itacitinib INCB039110 JAK1 Inhibitor 8 Itacitinib (INCB039110) is a selective inhibitor of Janus kinase 1 (JAK1), which may inhibit cell proliferation (PMID: 25605813).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Hodgkin's lymphoma not applicable INCB040093 + Itacitinib Phase I Actionable In a Phase I trial, INCB040093 and INCB039110 combination treatment resulted in complete response in 22% (2/9) of Hodgkin's lymphoma patients, with an objective response rate of 67% (J Clin Oncol 33, 2015 (suppl; abstr 8558)). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01905813 Phase I INCB040093 + Itacitinib INCB040093 Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies Active, not recruiting